An extensive literature review was performed across PubMed, Scopus, and Web of Science using key terms such as “IL-17,” “Th17,” “autoimmune diseases,” “neuroinflammation,” and “monoclonal antibodies.” Studies published between 1993 and 2025 focused on the molecular processes of IL-17 cytokines, their involvement in inflammation and tissue repair, and the potential for therapeutic strategies aimed at modulating the IL-17/IL-17R pathway. The gene discussed is IL17RA; the disease is autoimmune disease.